The CB₁ receptor antagonist/inverse agonist rimonabant (SR141716A; 3 mg/kg i.p.), but not the cannabinoid receptor agonist HU210 (100µg/kg i.p.) or the CB₂ receptor antagonist SR144528 (3 mg/kg i.p.) potentiates lipopolysaccharide (LPS; 100µg/kg i.p.)-induced increases in plasma corticosterone in rats. Corticosterone levels were measured 2 hours post-LPS or saline and rats received cannabinoid or vehicle injections 30 minutes prior to LPS administration. Data are expressed as means ± S.E.M. (n=6–8 per group). **P<0.01 vs. Vehicle+Saline (black line). †P<0.05 vs. Vehicle+LPS (Student–Newman–Keuls post hoc test following ANOVA). Reproduced with permission from Roche et al. (2006).